|Former: Atención Farmacéutica|
|Journal edited by Rasgo Editorial since 1983|
Virginia Hernández Corredoira
EDITOR IN CHIEF
Manuela Velázquez Prieto
Jaime E. Poquet Jornet
Ramón Jódar Masanés
Lluís Campins Bernadas
Tomás Casasín Edo
Juan Carlos Juárez Giménez
Carles Quiñones Ribas
Volume 21 - Issue 4, October-December 2019
REAL-WORLD EFFECTIVENESS OF THE COMBINED TREATMENT ELBASVIR/GRAZOPREVIR ± RIBAVIRIN IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1/4
DEL RIO-VALENCIA JUAN CARLOS, ALCARAZ SÁNCHEZ JUAN JOSÉ, LINARES ALARCÓN ARANZAZU, MUÑOZ CASTILLO ISABEL
lntroduction and objective: Antiviral treatment for HCV infection has significantly improved since the advent of direct-acting antiviral (DAA), yet a number of issues remain unmet. There are very limited treatment options for patients with chronic kidney disease (CKD), patients with resistance-associated substitutions (RAS) and patients with coadministered drugs due to complicated diseases. The combined treatment elbasvir (EBR) and grazoprevir (GZR) has consistently shown high rates of sustained virologic response (SVR) in patients with chronic HCV and GT 1 and 4. This regimen is currently one of the two licensed treatment, together with glecaprevir/pibrentasvir, used in individuals with advanced chronic kidney disease requiring hemodialysis. The aim of this analysis was to evaluate the effectiveness of EBR/GZR in real-world data.
Method: Retrospective and observational study carried out from January 2017 to January 2019. Inclusion criteria: patients with HCV infection treated with EBR/ GZR for 12, 16 or 24 weeks during study period. Exclusion criteria: patients from whom adequate clinical and/or analytical information was not available for fur- ther analysis. The variables collected were expressed as median (range) or mean and standard deviation. All analyses were performed by using SPSS v.17.
Results: 28 patients were analyzed achieving SVR12 96.42% (27/28) of them. The patients with HCV genotype (GT) 1a or GT1b or GT4 achieved SVR12, only one naive-non cirrhotic patient, with viral load higher than 800,000 IU/ml, did not get SVR12. Patients diagnosed with chronic kidney failure were treated too. Concretely, three HCV-GT1b infected patients who suffered from stage 5 chronic kidney failure (<15 ml/min) and one patient from stage 4 (<30 ml/min) achieving SVR12 all of them and maintained their renal function at the end of the treatment. Conclusion: The EBV/GZR regimen could be considered a therapeutic alter- native to other combinations of DAA, in patients with genotype 1 and 4, both mono and coinfected with HIV, with and without cirrhosis and patients with
chronic kidney disease.
KIDNEY DISEASE – ELBASVIR/GRAZOPREVIR – GENOTYPE 1 AND 4 –